Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12498658 | 0.98 | LOXL2 (0.53) | LOXL2KDM4EGAAALDH1A1MAPT | |
| SCHEMBL2742567 | 0.87 | TSHR (0.61) | KDM4EGAAALDH1A1MAPTHPGD | |
| SCHEMBL1361424 | 0.87 | HPGD (0.54) | LOXL2KDM4EGAAALDH1A1MAPT | |
| SCHEMBL30362267 | 0.87 | HPGD (0.54) | LOXL2KDM4EGAAALDH1A1MAPT | |
| SCHEMBL5503225 | 0.86 | PPARG (0.51) | KDM4EGAAALDH1A1MAPTHPGD | |
| Hydrochloric Acid SCHEMBL12499434 | 0.86 | TAAR1 (0.62) | KDM4EGAAALDH1A1MAPTHPGD | |
| SCHEMBL4241664 | 0.85 | CA12 (0.51) | KDM4EGAAALDH1A1MAPTHPGD | |
| SCHEMBL18310130 | 0.85 | KLKB1 (0.48) | LOXL2KDM4EGAAALDH1A1MAPT | |
| SCHEMBL4307061 | 0.83 | KDM4E (0.51) | KDM4EGAAALDH1A1MAPTHPGD | |
| SCHEMBL2772618 | 0.83 | HTT (0.48) | KDM4EGAAALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| EP-4565562-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| CN-119790036-A | Pyrrolidine-2-carboxamide derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024028603-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024028603-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2318375-B1 | IMIDAZOLE CARBOXAMIDES | LILLY CO ELI (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2488491-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-8017607-B2 | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2011098398-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011045257-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | BARTKOVITZ DAVID JOSEPH | 2011-04-14 | — | — | US | disclosed |
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | LOXL2 498/4885KDM4E 4232/4885GAA 4771/4885 |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | MDM2, TP53, TP53BP1 | LOXL2 3686/4885KDM4E 1931/4885GAA 2559/4885 |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | CYP3A4, CYP2C9, AADAC | LOXL2 4786/4885KDM4E 449/4885GAA 690/4885 |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | LOXL2 3755/4885KDM4E 272/4885GAA 2654/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | LOXL2 3977/4885KDM4E 1351/4885GAA 777/4885 |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | LOXL2 3977/4885KDM4E 1351/4885GAA 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.